Berkeley, CA – According to filings with the U.S. Securities and Exchange Commission, Valitor is raising $32,741,264.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Wesley Jackson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Valitor
Valitor, Inc. is a biotechnology company founded to develop advanced, protein-based drugs. Using our core technology, we can modify existing biological therapies to achieve substantial control over their pharmacological properties. Our mission is to develop a new generation of biologic therapies that will reduce the costs associated with effective treatment of these diseases. We also aim to improve the patients quality of life by reducing the required frequency of therapeutic administration. We have initiated a pipeline of drug products that will be used to treat a variety of diseases currently imposing a significant financial burden on the nations healthcare system. Valitor is currently hiring! Visit: http://www.valitorbio.com/careers.html for more details.

To learn more about Valitor, visit http://www.valitorbio.com

Contact:
Wesley Jackson, President and Chief Executive Officer
510-813-8611
https://www.linkedin.com/in/wesleymjackson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved